{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:42:48Z","timestamp":1762854168271,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.gofs.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:58:12Z","timestamp":1549004292000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumeurs \u00e9pith\u00e9liales malignes de l\u2019ovaire\u00a0: place de la chimioth\u00e9rapie intrap\u00e9riton\u00e9ale et de la chimioth\u00e9rapie hyperthermique intrap\u00e9riton\u00e9ale (CHIP). Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa"],"prefix":"10.1016","volume":"47","author":[{"given":"N.","family":"Bakrin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0230","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.gofs.2019.01.001_bib0240","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group Study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2009.05.034","article-title":"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer","volume":"114","author":"Yen","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0260","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/IGC.0000000000000389","article-title":"Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer","volume":"25","author":"Suidan","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0265","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.gofs.2019.01.001_bib0270","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.gofs.2019.01.001_bib0275","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.gofs.2019.01.001_bib0280","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Nat Can Inst"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2008.11.021","article-title":"Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma","volume":"112","author":"Chin","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.001_bib0290","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0b013e31821ee777","article-title":"Feasibility of a modified outpatient regimen of intravenous\/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study","volume":"21","author":"Oaknin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0295","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000356758","article-title":"Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer","volume":"59","author":"Battelli","year":"2013","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.001_bib0305","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ajog.2013.03.012","article-title":"Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers","volume":"208","author":"Teefey","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2011.07.016","article-title":"Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group Study","volume":"123","author":"Dizon","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"35","key":"10.1016\/j.gofs.2019.01.001_bib0315","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2011.36.1352","article-title":"Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II\/III epithelial ovarian cancer","volume":"29","author":"Konner","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0320","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2011.05.022","article-title":"Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer","volume":"122","author":"Landrum","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0325","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3802\/jgo.2013.24.4.359","article-title":"Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study","volume":"24","author":"Blinman","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0330","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Miyagi","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2019.01.001_bib0335","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1525-1438.2008.01192.x","article-title":"Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer","volume":"18","author":"Nagao","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0340","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2009.10.054","article-title":"Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer","volume":"116","author":"Gray","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0345","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejogrb.2010.05.033","article-title":"The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer","volume":"152","author":"Kim","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2015.11.005","article-title":"A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer","volume":"140","author":"Bouchard-Fortier","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2010.12.358","article-title":"A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"121","author":"Morgan","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0360","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2012.08.037","volume":"127","author":"Gould","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2019.01.001_bib0365","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/IGC.0b013e3181a29dfe","article-title":"Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0370","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/IGC.0b013e318234f927","article-title":"Intravenous\/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study","volume":"22","author":"Nagao","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0375","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/annonc\/mdx754","article-title":"OV21\/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer","volume":"29","author":"Provencher","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0380","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.08.026","article-title":"The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer","volume":"119","author":"Kothari","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0385","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ygyno.2017.05.032","article-title":"Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women","volume":"146","author":"Crim","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0390","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2019.01.001_bib0400","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.gofs.2019.01.001_bib0405","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.001_bib0410","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3\u00a0randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.gofs.2019.01.001_bib0415","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.gofs.2019.01.001_bib0420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","article-title":"Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer","volume":"142","author":"Gouy","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0425","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1245\/s10434-008-0299-y","article-title":"Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study","volume":"16","author":"Lim","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0430","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ygyno.2007.03.022","article-title":"Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma","volume":"106","author":"Lentz","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2019.01.001_bib0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-015-0329-5","article-title":"The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer","volume":"16","author":"van Driel","year":"2015","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2019.01.001_bib0440","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","article-title":"Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer. Is there any difference?","volume":"25","author":"Cascales-Campos","year":"2016","journal-title":"Surg Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2019.01.001_bib0445","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/02656736.2014.991766","article-title":"Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma","volume":"31","author":"Rettenmaier","year":"2015","journal-title":"Int J Hyperthermia"},{"issue":"8","key":"10.1016\/j.gofs.2019.01.001_bib0225","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ejso.2013.12.028","article-title":"Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"40","author":"Chia","year":"2014","journal-title":"Eur J Surg Oncol"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718919300017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718919300017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:38:16Z","timestamp":1762853896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718919300017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2468718919300017"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2019.01.001","relation":{},"ISSN":["2468-7189"],"issn-type":[{"type":"print","value":"2468-7189"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumeurs \u00e9pith\u00e9liales malignes de l\u2019ovaire\u00a0: place de la chimioth\u00e9rapie intrap\u00e9riton\u00e9ale et de la chimioth\u00e9rapie hyperthermique intrap\u00e9riton\u00e9ale (CHIP). Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}